• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Early response observed in pediatric patients with relapsed/refractory Burkitt lymphoma treated with chimeric antigen receptor T cells.

作者信息

Zhang Wenqun, Yang Jing, Zhou Chunju, Hu Bo, Jin Ling, Deng Biping, Liu Yang, Wang Shan, Chang Alex H, Du Juan, Gao Zifen, Zhang Yonghong

机构信息

Department of Pediatric Lymphoma, Beijing Boren Hospital, Beijing, China.

Department of Hematology Oncology and.

出版信息

Blood. 2020 Jun 25;135(26):2425-2427. doi: 10.1182/blood.2019002008.

DOI:10.1182/blood.2019002008
PMID:32321169
Abstract
摘要

相似文献

1
Early response observed in pediatric patients with relapsed/refractory Burkitt lymphoma treated with chimeric antigen receptor T cells.在接受嵌合抗原受体T细胞治疗的复发/难治性伯基特淋巴瘤儿科患者中观察到早期反应。
Blood. 2020 Jun 25;135(26):2425-2427. doi: 10.1182/blood.2019002008.
2
Rituximab in a child with relapsed Burkitt lymphoma.利妥昔单抗用于一名复发性伯基特淋巴瘤患儿。
Pediatr Blood Cancer. 2007 Aug;49(2):218. doi: 10.1002/pbc.20957.
3
Induction of long-term remission of a relapsed childhood B-acute lymphoblastic leukemia with rituximab chimeric anti-CD20 monoclonal antibody and autologous stem cell transplantation.利妥昔单抗（嵌合抗CD20单克隆抗体）联合自体干细胞移植诱导复发儿童B系急性淋巴细胞白血病长期缓解
J Pediatr Hematol Oncol. 2003 Apr;25(4):327-9. doi: 10.1097/00043426-200304000-00013.
4
Sustained complete remission following a combination of very low intensity chemotherapy with rituximab in an elderly patient with Burkitt's lymphoma.一名老年伯基特淋巴瘤患者接受极低强度化疗联合利妥昔单抗治疗后获得持续完全缓解。
Haematologica. 2002 Jan;87(1):ELT04.
5
In Burkitt lymphoma patients who relapse after induction with a short-intensive chemoimmunotherapy protocol, aggressive salvage chemotherapy therapy is ineffective: a single-center retrospective study.在采用短期强化化疗免疫疗法方案诱导治疗后复发的伯基特淋巴瘤患者中，积极的挽救性化疗无效：一项单中心回顾性研究。
Ann Hematol. 2017 Sep;96(9):1573-1575. doi: 10.1007/s00277-017-3044-4. Epub 2017 Jun 16.
6
Successful salvage chemotherapy for isolated central nervous system (CNS) relapse in Burkitt lymphoma: monocentric experience of 3 pediatric patients.伯基特淋巴瘤孤立性中枢神经系统（CNS）复发的成功挽救化疗：3例儿科患者的单中心经验
J Pediatr Hematol Oncol. 2008 Dec;30(12):972-5. doi: 10.1097/MPH.0b013e31818b3584.
7
Burkitt's lymphoma: single-centre experience with modified BFM protocol.伯基特淋巴瘤：采用改良BFM方案的单中心经验
Clin Lab Haematol. 2002 Apr;24(2):111-4. doi: 10.1046/j.1365-2257.2002.00429.x.
8
Secondary choroidal lymphoma in a child treated for Burkitt lymphoma.一名接受伯基特淋巴瘤治疗的儿童发生继发性脉络膜淋巴瘤。
J AAPOS. 2011 Feb;15(1):94-5. doi: 10.1016/j.jaapos.2010.12.004.
9
Relapsed/refractory Burkitt lymphoma and HIV infection.复发性/难治性伯基特淋巴瘤与HIV感染
Int J STD AIDS. 2018 Jun;29(7):695-703. doi: 10.1177/0956462417748239. Epub 2017 Dec 21.
10
Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma.复发或难治性伯基特淋巴瘤和高级别B细胞白血病/淋巴瘤成人患者的治疗结果。
Am J Hematol. 2017 Jun;92(6):E114-E117. doi: 10.1002/ajh.24720. Epub 2017 Apr 18.

引用本文的文献

1
Influencing factors and solution strategies of chimeric antigen receptor T-cell therapy (CAR-T) cell immunotherapy.嵌合抗原受体 T 细胞疗法（CAR-T）细胞免疫疗法的影响因素及解决方案策略。
Oncol Res. 2024 Aug 23;32(9):1479-1516. doi: 10.32604/or.2024.048564. eCollection 2024.
2
Advances in research on factors affecting chimeric antigen receptor T-cell efficacy.嵌合抗原受体 T 细胞疗效影响因素的研究进展。
Cancer Med. 2024 Jun;13(11):e7375. doi: 10.1002/cam4.7375.
3
Refractory Burkitt Lymphoma: Diagnosis and Interventional Strategies.
难治性伯基特淋巴瘤：诊断与介入策略
Blood Lymphat Cancer. 2024 Mar 13;14:1-15. doi: 10.2147/BLCTT.S407804. eCollection 2024.
4
Broadening the horizon: potential applications of CAR-T cells beyond current indications.拓宽视野：CAR-T 细胞在现有适应证之外的潜在应用。
Front Immunol. 2023 Nov 27;14:1285406. doi: 10.3389/fimmu.2023.1285406. eCollection 2023.
5
CAR-T Cell Therapy in the Treatment of Pediatric Non-Hodgkin Lymphoma.嵌合抗原受体T细胞疗法治疗儿童非霍奇金淋巴瘤
J Pers Med. 2023 Nov 10;13(11):1595. doi: 10.3390/jpm13111595.
6
Bone Marrow Aplasia after CAR-T-Cell Therapy for Relapsed/Refractory Burkitt's Lymphoma.CAR-T 细胞治疗复发/难治性伯基特淋巴瘤后骨髓再生不良。
Med Sci (Basel). 2023 Oct 12;11(4):67. doi: 10.3390/medsci11040067.
7
Targeting CD22 for B-cell hematologic malignancies.以CD22为靶点治疗B细胞血液系统恶性肿瘤。
Exp Hematol Oncol. 2023 Oct 11;12(1):90. doi: 10.1186/s40164-023-00454-7.
8
Case Report: Unedited allogeneic chimeric antigen receptor T cell bridging to conditioning-free hematopoietic stem cell transplantation for a child with refractory Burkitt lymphoma.病例报告：未编辑的同种异体嵌合抗原受体 T 细胞桥接无预处理造血干细胞移植治疗难治性伯基特淋巴瘤患儿。
Front Immunol. 2023 Sep 6;14:1219872. doi: 10.3389/fimmu.2023.1219872. eCollection 2023.
9
Feasibility and outcomes after dose reduction of immunochemotherapy in young adults with Burkitt lymphoma and leukemia: results of the BURKIMAB14 trial.年轻成人伯基特淋巴瘤和白血病患者免疫化疗剂量减少的可行性和结局：BURKIMAB14 试验结果。
Haematologica. 2024 Feb 1;109(2):543-552. doi: 10.3324/haematol.2023.283342.
10
FAP-targeted CAR-T suppresses MDSCs recruitment to improve the antitumor efficacy of claudin18.2-targeted CAR-T against pancreatic cancer.FAP 靶向 CAR-T 抑制 MDSCs 募集，以提高 Claudin18.2 靶向 CAR-T 对胰腺癌的抗肿瘤疗效。
J Transl Med. 2023 Apr 12;21(1):255. doi: 10.1186/s12967-023-04080-z.